Introduction: The aim of the study was to compare the prostate cancer (PCa) detection rate of systematic transrectal ultrasound-guided biopsies (TRUS-bx) and multiparametric-MRI targeted biopsies (mp-MRI-bx) in a repeat biopsy setting and evaluate the clinical significance following an “MRI-targeted-only” approach. Materials and Methods: Patients with prior negative biopsies underwent prostatic multiparametric-MRI that was scored using the Prostate Imaging Reporting and Data System (PI-RADS) classification. All underwent both repeated TRUS-bx and mp-MRI-bx using image fusion of any PI-RADS ≥3 lesion. Biopsy results from TRUS-bx, mp-MRI-bx, and the combination were compared. Results: PCa was detected in 89 out of 206 (43%) patients. Of these, 64 (31%) and 74 (36%) patients were detected using mp-MRI-bx and TRUS-bx, respectively. Overall, mp-MRI-bx detected fewer patients with low-grade (Gleason score [GS] 3 + 3) cancers (14/64 vs. 41/74) and more patients with intermediate/high-grade cancers (GS ≥3 + 4) (50/64 vs. 33/74) using fewer biopsy cores compared with TRUS-bx (p < 0.001). Using an “MRI-targeted-only” approach in men with PI-RADS ≥3 lesions reduced the number of men requiring repeated biopsies by 50%, decreased low-grade cancer diagnoses by 66%, and increased intermediate/high-grade cancer diagnoses by 52%. Conclusions: MRI-targeted biopsies have a high detection rate for significant PCa in patients with prior negative transrectal ultrasound-guided biopsies and preferentially detect intermediate/high-grade compared with low-grade tumors.

Journal Section:
Editor's choice
Keywords:
Prostate cancer, Biopsy, Magnetic resonance imaging, Ultrasonography, Outcome
1.
Shariat SF, Roehrborn CG: Using biopsy to detect prostate cancer. Rev Urol 2008;10:262-280.
2.
Ploussard G, Nicolaiew N, Marchand C, Terry S, Vacherot F, Vordos D, et al: Prospective evaluation of an extended 21-core biopsy scheme as initial prostate cancer diagnostic strategy. Eur Urol 2014;65:154-161.
3.
Maccagnano C, Gallina A, Roscigno M, Raber M, Capitanio U, Saccà A, et al: Prostate saturation biopsy following a first negative biopsy: state of the art. Urol Int 2012;89:126-135.
4.
Ukimura O, Coleman JA, de la Taille A, Emberton M, Epstein JI, Freedland SJ, et al: Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care. Eur Urol 2013;63:214-230.
5.
Zaytoun OM, Moussa AS, Gao T, Fareed K, Jones JS: Office based transrectal saturation biopsy improves prostate cancer detection compared to extended biopsy in the repeat biopsy population. J Urol 2011;186:850-854.
6.
Boccon-Gibod LM, Dumonceau O, Toublanc M, Ravery V, Boccon-Gibod LA: Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen features. Eur Urol 2005;48:895-859.
7.
Epstein JI, Feng Z, Trock BJ, Pierorazio PM: Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol 2012;61:1019-1024.
8.
Sciarra A, Barentsz J, Bjartell A, Eastham J, Hricak H, Panebianco V, et al: Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol 2011;59:962-977.
9.
Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, et al: ESUR prostate MR guidelines 2012. Eur Radiol 2012;22:746-757.
10.
Moore CM, Robertson NL, Arsanious N, Middleton T, Villers A, Klotz L, et al: Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol 2013;63:125-140.
11.
Delongchamps NB, Peyromaure M, Schull A, Beuvon F, Bouazza N, Flam T, et al: Prebiopsy magnetic resonance imaging and prostate cancer detection: comparison of random and targeted biopsies. J Urol 2013;189:493-499.
12.
Sonn GA, Chang E, Natarajan S, Margolis DJ, Macairan M, Lieu P, et al: Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen. Eur Urol 2014;65:809-815.
13.
Hambrock T, Hoeks C, Hulsbergen-van de Kaa C, Scheenen T, Fütterer J, Bouwense S, et al: Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort. Eur Urol 2012;61:177-184.
14.
Siddiqui MM, Rais-Bahrami S, Truong H, Stamatakis L, Vourganti S, Nix J, et al: Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol 2013;64:713-719.
15.
Boesen L, Noergaard N, Chabanova E, Logager V, Balslev I, Mikines K, et al: Early experience with multiparametric magnetic resonance imaging-targeted biopsies under visual transrectal ultrasound guidance in patients suspicious for prostate cancer undergoing repeated biopsy. Scand J Urol 2015;49:25-34.
16.
Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, et al: Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 2011;59:477-494.
17.
Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al: PI-RADS prostate imaging - reporting and data system: 2015, Version 2. Eur Urol 2016;69:16-40.
18.
Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL: The 2005 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma. Am J Surg Pathol 2005;29:1228-1242.
19.
Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, et al: The 2014 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic Carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 2016;40:244-252.
20.
Vourganti S, Rastinehad A, Yerram NK, Nix J, Volkin D, Hoang A, et al: Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies. J Urol 2012;188:2152-2157.
21.
Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N, et al: Comparison of MR/ultrasound fusion - guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA 2015;313:390.
22.
Filson CP, Natarajan S, Margolis DJ, Huang J, Lieu P, Dorey FJ, et al: Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: the role of systematic and targeted biopsies. Cancer 2016;122:884-892.
23.
Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al: EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2017;71:618-629.
24.
Delongchamps NB, Lefèvre A, Bouazza N, Beuvon F, Legman P, Cornud F: Detection of significant prostate cancer with magnetic resonance targeted biopsies - should transrectal ultrasound-magnetic resonance imaging fusion guided biopsies alone be a standard of care? J Urol 2015;193:1198-1204.
25.
Turkbey B, Merino MJ, Gallardo EC, Shah V, Aras O, Bernardo M, et al: Comparison of endorectal coil and nonendorectal coil T2W and diffusion-weighted MRI at 3 Tesla for localizing prostate cancer: correlation with whole-mount histopathology. J Magn Reson Imaging 2014;39:1443-1448.
26.
Tan N, Margolis DJ, Lu DY, King KG, Huang J, Reiter RE, et al: Characteristics of detected and missed prostate cancer foci on 3-T multiparametric MRI using an endorectal coil correlated with whole-mount thin-section histopathology. AJR Am J Roentgenol 2015;205:W87-W92.
27.
Thompson JE, van Leeuwen PJ, Moses D, Shnier R, Brenner P, Delprado W, et al: The diagnostic performance of multiparametric magnetic resonance imaging to detect significant prostate cancer. J Urol 2016;195:1428-1435.
28.
Russo F, Regge D, Armando E, Giannini V, Vignati A, Mazzetti S, et al: Detection of prostate cancer index lesions with multiparametric magnetic resonance imaging (mp-MRI) using whole-mount histological sections as the reference standard. BJU Int 2016;118:84-94.
29.
Ploussard G, Epstein JI, Montironi R, Carroll PR, Wirth M, Grimm MO, et al: The contemporary concept of significant versus insignificant prostate cancer. Eur Urol 2011;60:291-303.
30.
Moore CM, Kasivisvanathan V, Eggener S, Emberton M, Fütterer JJ, Gill IS, Grubb RL, et al: Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol 2013;64:544-552.
© 2017 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2017
You do not currently have access to this content.